A clinical trial of a “cannabinoid painkiller” in France has left one person in a coma and five others critically ill. In response, the French health ministry has put a halt to the trials in what it describes as “a serious accident.”
Earlier today in a statement, the French Ministry of Social Affairs, Health, and Women’s Rights announced that a serious incident had occurred as part of a Phase 1 clinical trial on an oral drug being developed by a European lab. The trial was being conducted in a licensed private institution to evaluate the safety and tolerability of a particular molecule in health volunteers. The accident resulted in the hospitalization of six volunteers at the University Hospital of Rennes. One of the volunteers is in intensive care, apparently “brain dead.”
The ministry has suspended the trial, and the firm is recalling all volunteers. It’s not known how many people were involved in the drug trial. The name of the private company was not disclosed by the ministry, but French media outlet iTELE claims that the drug, a pain reliever containing cannabis, is being developed by Biotrial. Also, The Verge points out that Biotrial’s website contains a call for volunteers to participate in drug trials at Rennes and Newark, New Jersey. Biotrial has yet to issue a formal response, but the firm acknowledged that it will be participating in a press conference later today.
French Minister Marisol Touraine was in quoted in the BBC as saying her government will “get to the bottom… of this tragic accident.” The Paris prosecutor’s office has now launched an investigation.
Clinical trials are standard practice before new medicines can be administered to patients. By performing these tests, drug developers can collect information about the safety and efficacy of unproven medicines. Without volunteers, it would be exceptionally difficult, if not impossible, to bring new drugs to market. That said, drug companies typically don’t initiate Phase I trials (there are three phases in the clinical trial process) unless they’re reasonably certain the drug is safe, usually after prior testing on animal models.
As for this breaking story, it will be interesting to see what kind of due diligence was performed by the company prior to launching the clinical trials.